Sugi Predict

Sugi Predict / Compounds / SCHEMBL794103

SCHEMBL794103

SCHEMBL794103

NS(=O)(=O)c1ccccc1S(=O)(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 5/20 0.63
▸ CA2 P00918 9/20 0.58
▸ CA1 P00915 8/20 0.58
▸ CA12 O43570 6/20 0.58
▸ CA9 Q16790 6/20 0.58
▸ CA6 P23280 4/20 0.58
▸ CA7 P43166 4/20 0.58
▸ CA4 P22748 3/20 0.58
▸ CA5A P35218 3/20 0.58
▸ CA5B Q9Y2D0 3/20 0.58
▸ CA14 Q9ULX7 2/20 0.58
▸ CA13 Q8N1Q1 2/20 0.58
▸ CA3 P07451 1/20 0.58
▸ PLA2G7 Q13093 1/20 0.58
▸ CYP2C9 P11712 1/20 0.52
▸ POLB P06746 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29469862 1.00 HTR6 (0.63) HTR6CA2CA1CA12CA9
Hydrochloric Acid SCHEMBL4616714 0.98 HTR6 (0.61) HTR6CA2CA1CA12CA9
SCHEMBL30564946 0.98 HTR6 (0.61) HTR6CA2CA1CA12CA9
SCHEMBL29155810 0.98 HTR6 (0.61) HTR6CA2CA1CA12CA9
Benzenesulfonamide SCHEMBL16540189 0.96 CA1 (0.67) HTR6CA2CA1CA12CA9
SCHEMBL8080841 0.88 HTR6 (0.72) HTR6CA2CA1CA12CA9
SCHEMBL11779771 0.85 HTR6 (0.61) HTR6CA2CA1CA12CA9
SCHEMBL10750176 0.85 CA2 (0.67) HTR6CA2CA1CA12CA9
SCHEMBL14060214 0.84 CA2 (0.57) HTR6CA2CA1CA12CA9
SCHEMBL202947 0.83 CA2 (0.70) CA2CA1CA12CA9CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012035061-A1 PROCESS FOR THE PREPARATION OF 1,2-DIAMINES BY INTERMOLECULAR TRANSFER OF TWO NITROGEN GROUPS ONTO ALKENES AND INTERMEDIATES THEREOF INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) (ES) 2012-03-22 — — WO claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 — — EP claimed
EP-1999121-A1 NOVEL TETRALINS AS 5-HT6 MODULATORS AstraZeneca AB (SE) 2008-12-10 — — EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 — — WO claimed
EP-1888517-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR AstraZeneca AB (SE) 2008-02-20 — — EP claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 — — EP claimed
WO-2007108742-A1 NOVEL TETRALINS AS 5-HT6 MODULATORS ASTRAZENECA AB (SE) 2007-09-27 — — WO claimed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 — — WO claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO claimed
EP-1248787-B1 NOVEL SUBTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM WARNER LAMBERT CO (US) 2004-10-06 — — EP claimed
EP-4709718-A1 6-SUBSTITUTED-3-PHENYL-ISOINDOLIN-1-ONES AS CBL-B INHIBITORS SELECTIVE OVER C-CBL Genentech Inc. (US) 2026-03-18 — — EP disclosed
WO-2024140935-A1 B7H3 ANTIBODY DRUG CONJUGATES BEIGENE, LTD. (KY) 2024-07-04 — — WO disclosed
WO-2024067811-A1 LIGAND-DRUG CONJUGATE OF EXATECAN ANALOGUE, AND MEDICAL USE THEREOF BEIGENE, LTD. (KY) 2024-04-04 — — WO disclosed
WO-2024056019-A1 BICYCLIC COMPOUNDS AS CDK INHIBITORS BEIGENE, LTD. (KY) 2024-03-21 — — WO disclosed
EP-4330254-A1 MODULATORS OF TREX1 Constellation Pharmaceuticals, Inc. (US) 2024-03-06 — — EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 — — US disclosed
WO-2006126939-A1 NOVEL 8-SULFONYLAMINO-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR ASTRAZENECA AB (SE) 2006-11-30 — — WO disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 — — WO disclosed
EP-1248787-A2 NOVEL SUBTITUTED PYRAZOLO[4, 3-E]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM WARNER-LAMBERT COMPANY (US) 2002-10-16 — — EP disclosed
WO-2001049689-A2 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM WARNER-LAMBERT COMPANY (US) 2001-07-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 HTR6 3789/4885CA2 2749/4885CA1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.